Next 10 |
home / stock / mdclf / mdclf news
2024-05-08 10:13:13 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited 2024 Q1 - Results - Earnings Call Presentation Teva Pharmaceutical Industries: Potential Outweighs Concerns Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportu...
2024-05-08 07:40:43 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries: Potential Outweighs Concerns Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Pos...
2024-04-16 12:54:17 ET More on AbbVie AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% AbbVie working with FDA after reports of fake Botox versions ...
Medincell will receive an upfront payment of $35 million and is eligible for up to $1.9 billion in potential development and commercial milestones, plus royalties on worldwide sales. Medincell and AbbVie will co-develop, and AbbVie will commercialize up to six cutting-edge long-acting inj...
Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM. If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission...
Guidance for 2024 UZEDY Teva’s revenue: ~ $80 million Olanzapine LAI ongoing Phase 3: 675 patients (recruitment completed), 62% of the targeted 3,600 injections performed, no PDSS (Post injection Delirium/Sedation Syndrome) observed MedinCell (Paris:MEDCL): Access...
Teva Pharmaceutical Industries Ltd. announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase 3 clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference. Results of the study are expected in the second hal...
MedinCell’s partner Teva to receive R&D funding from Royalty Pharma of up to $125 million to further accelerate the development of olanzapine LAI, a long-acting subcutaneous injectable olanzapine for schizophrenia using MedinCell’s technology. ( Access here Teva and Royalty Ph...
Grace Kim brings two decades’ experience in financial strategy and business development for private and public companies She has a deep track record of leveraging high-impact relationships with Wall Street to optimize capital development strategy and maximize long-term value creati...
Enrolment is complete following the randomization of 151 patients across seven centers in the US The study was initiated in November 2022 and is proceeding as planned with efficacy results anticipated in Q1 2024 F14 (mdc-CWM) is a sustained-release formulation of the non-steroidal...
News, Short Squeeze, Breakout and More Instantly...
Medical Intelligence Technologies Inc Company Name:
MDCLF Stock Symbol:
OTCMKTS Market:
Medincell will receive an upfront payment of $35 million and is eligible for up to $1.9 billion in potential development and commercial milestones, plus royalties on worldwide sales. Medincell and AbbVie will co-develop, and AbbVie will commercialize up to six cutting-edge long-acting inj...
Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM. If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission...
Guidance for 2024 UZEDY Teva’s revenue: ~ $80 million Olanzapine LAI ongoing Phase 3: 675 patients (recruitment completed), 62% of the targeted 3,600 injections performed, no PDSS (Post injection Delirium/Sedation Syndrome) observed MedinCell (Paris:MEDCL): Access...